Bengaluru-based private medtech firm Tricog Health has announced a goal to complete 100 million cardiac screenings by 2030. The company uses AI-powered tools to accelerate heart condition diagnosis and bridge rural-urban healthcare gaps. As a private, unlisted startup, it does not trade on public stock exchanges.
Scaling AI-Driven Diagnostics
Tricog Health, a Bengaluru-based medtech startup, has set an ambitious objective to facilitate 100 million cardiac screenings within the next six years. Since its founding in 2014, the company has focused on using artificial intelligence to modernize heart health diagnostics. By deploying AI-enabled devices like the VCardia and the InstaECG platform, the firm aims to identify over 140 types of cardiac conditions quickly, transmitting data to a cloud platform for rapid verification by a network of specialist doctors. This model is designed to significantly reduce the time between symptom presentation and medical intervention, which is crucial for emergency care.
Business Model and Market Presence
The company operates using a hub-and-spoke model, which is intended to connect remote primary care clinics with advanced tertiary care facilities. In practice, this allows healthcare providers in smaller towns to access specialist opinions without needing to transport patients immediately to major cities. The firm has already established a presence in 14 countries across the Global South and has integrated its technology into various public and private healthcare infrastructures. Financially, Tricog Health operates as a private entity backed by venture capital, with approximately $30 million in funding raised from investors like Omron Healthcare and the Sony Innovation Fund. Recent reports place its operating revenue in the range of ₹50 to ₹100 crore for the 2025 financial year.
Sector Challenges and Risks
While the expansion of digital health tools is a positive development for patient access, the medtech sector carries specific risks that stakeholders often monitor. One of the primary hurdles for companies in this space is the complex regulatory environment. Diagnostic tools must constantly meet evolving medical standards and licensing requirements across different states and countries. Furthermore, handling sensitive patient data requires robust security infrastructure to manage privacy risks effectively.
Another significant challenge is maintaining profitability in a price-sensitive market like India. The cost of technology must be balanced against the need for affordability to ensure widespread adoption. Additionally, the company faces competition from other digital health platforms and traditional diagnostic centers. Sustained growth will depend on the firm’s ability to scale its operations while managing capital spending and proving the long-term clinical efficacy of its AI tools.
For industry observers and those following the healthcare sector, the key developments to track will include the adoption rate of these AI platforms in public health systems, the company’s ability to secure further funding for expansion, and its success in maintaining high diagnostic accuracy as volumes increase. As a private company, its progress serves as an indicator of the broader potential for AI-led diagnostic solutions to reshape cardiac care in emerging markets.